Medical News Today: Can you prevent psoriatic arthritis?

It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news

Related Links:

TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsSecukinumab appears to be cost effective compared with other DMARDs for the treatment of active PsA in biologic-na ïve and biologic-experienced populations in Germany.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
Authors: Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS Abstract Psoriatic arthritis (PsA) affects up to 30% of patients with psoriasis and may include musculoskeletal manifestations such as enthesitis. Enthesitis is associated with joint damage, and early detection and treatment are essential to management of the disease. Traditionally assessed by clinical examination and conventional radiography, entheseal inflammation can now be more accurately assessed earlier in the disease using techniques such as ultrasound, magnetic resonance imaging, computed tomography, and molecular imaging. However, there is litt...
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Authors: Haddad A, Feld J, Zisman D Abstract Several screening questionnaires have been developed to identify patients with psoriatic arthritis (PsA) in the psoriasis population in dermatology and general practice settings1,2,3,4,5 However, the diagnosis of PsA using these questionnaires is a topic for debate, partly because of disease heterogeneity, and the complications from inconsistent performance results6,7,8,9. PMID: 31676694 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Authors: Lubrano E, Scriffignano S, Perrotta FM Abstract Introduction: Psoriatic Arthritis (PsA) is a chronic inflammatory disease characterized by psoriasis, synovitis, enthesitis, spondylitis and association with extra-articular manifestations and comorbidities. Treatment of PsA dramatically changed since the introduction of anti-TNF drugs which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease ...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
ConclusionsOverall, in this study with more than 70% of patients with moderate disease, patients reported high burden of disease and impact on QoL. This study demonstrates the importance of considering patient perspectives in treatment decisions that are critical for optimizing patient outcomes.FundingEli Lilly and Company.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
We report four cases of extensive AA successfully treated with apremilast.
Source: International Journal of Trichology - Category: Dermatology Authors: Source Type: research
Abstract OBJECTIVE: To compare the efficacy of secukinumab with that of placebo across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT) individual PsA core domains using pooled data from 4 phase 3 psoriatic arthritis (PsA) studies and 1 phase 3 ankylosing spondylitis (AS) study. METHODS: Data were pooled from 2049 patients with PsA participating in 4 on-label phase 3 PsA studies (FUTURE 2-5), and the efficacy of each GRAPPA-OMERACT PsA core domain (musculoskeletal disease activity, skin disease activity, pain, patient glob...
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
Abstract OBJECTIVE: The aim of this study was to compare patients with ankylosing spondylitis with psoriasis (ASP) and without psoriasis (AS), to axial PsA (axPsA) patients. METHODS: Two adult cohorts were recruited from the AS clinic: ASP and AS. These two cohorts were compared with two adult cohorts recruited from the PsA clinic: axPsA (radiographic sacroiliitis: ⩾bilateral grade 2 or unilateral grade 3 or 4); and Peripheral PsA. All patients were followed prospectively according to the same protocol. The demographic, clinical and radiographic variables were compared. Adjusted means were used to account f...
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Rheumatology (Oxford) Source Type: research
Conclusion: While tofacitinib has a wide array of immunoregulatory properties, making it a possible candidate for treating many dermatologic conditions refractory to other treatments, further testing is needed to better characterize its efficacy and utility moving forward, as well as its safety and adverse effect profile. PMID: 31581859 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Arthritis | Health | Learning | Psoriasis | Psoriatic Arthritis | Rheumatology | Universities & Medical Training